Boehringer Ingelheim, a German drugmaker, expressed its aspiration to launch survodutide, a drug candidate co-developed with Zealand Pharma (ZELA.CO), with the potential to treat obesity and fatty liver.
The anticipated launch is scheduled for either 2027 or 2028, contingent upon the outcome of trial data. The timeline for introduction hinges on the conclusive results from ongoing clinical trials.
On Monday, Carinne Brouillon, informed Reuters that it was unclear which of the drug’s two target indications would be launched first. She is head of Boehringer’s Human Pharma unit.
On Monday, Zealand’s stock rose after announcing with partner Boehringer that the drug had produced “groundbreaking” mid-stage trial results in the treatment of fatty liver disease, or MASH. This marked a significant development for the company.
Click here for more Business news.